IL15 and Alzheimer disease: In the case of IL-15 production by VSV-infected PBLs, an increased effect of EGb treatment was noticed, respectively, in AD from MedIL−15−α;ControlPBLs+VSV; before=23.7 pg/mL to MedIL−15−α;ControlPBLs+VSV; after=39.11 pg/mL and in controls from MedIL−15−α;ControlPBLs+VSV; before=40.71 pg/mL to MedIL−15−α;ControlPBLs+VSV; after=48.62 pg/mL.